References
- Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J. Hepatol.40(3), 472–477 (2004).
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin.61(2), 69–90 (2011).
- Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med.362(14), 1273–1281 (2010).
- Borger DR, Tanabe KK, Fan KC et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist17(1), 72–79 (2011).
- Dang L, White DW, Gross S et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature462(7274), 739–744 (2009).
- Ward PS, Patel J, Wise DR et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell17(3), 225–234 (2010).
- Xu W, Yang H, Liu Y et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell19(1), 17–30 (2011).
- Koivunen P, Lee S, Duncan CG et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature doi:10.1038/nature10898 (2012) (Epub ahead of print).
- Chowdhury R, Yeoh KK, Tian YM et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep.12(5), 463–469 (2011).
- Lu C, Ward PS, Kapoor GS et al.IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature doi:10.1038/nature10860 (2012) (Epub ahead of print).
- Figueroa ME, Abdel-Wahab O, Lu C et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell18(6), 553–567 (2010).
- Noushmehr H, Weisenberger DJ, Diefes K et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell17(5), 510–522 (2010).
- Turcan S, Rohle D, Goenka A et al.IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature doi:10.1038/nature10866 (2012) (Epub ahead of print).
- Andronesi OC, Kim GS, Gerstner E et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci. Transl. Med.4(116), 116ra4 (2012).
- Gross S, Cairns RA, Minden MD et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med.207(2), 339–344 (2010).
- Capper D, Simon M, Langhans CD et al. 2-hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int. J. Cancer doi:10.1002/ijc.26425 (2012) (Epub ahead of print).
- Jha P, Suri V, Jain A et al. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment. Neurosurgery67(6), 1681–1691 (2010).
- Kim YH, Pierscianek D, Mittelbronn M et al.TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J. Clin. Pathol.64(10), 850–852 (2011).
- Kim BH, Cho NY, Choi M, Lee S, Jang JJ, Kang GH. Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas. Arch. Pathol. Lab. Med.131(6), 923–930 (2007).
- Yang B, House MG, Guo M, Herman JG, Clark DP. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod. Pathol.18(3), 412–420 (2005).